As a result, HER3 inhibition led to significant anti-cancer effects in both KRAS wild-type and KRAS-mutant mCRC cells, and seribantumab, a humanized HER3 antibody, decreased tumor growth and sensitized tumors to fluorouracil chemotherapies in a liver injection orthotopic mCRC model [20]. This evidence concerns the gene ERBB3 and neoplasm.